Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug3616 | Virtual Family-Based Treatment Wiki | 1.00 |
drug3571 | VIR-7831 Wiki | 0.71 |
drug1786 | LY3819253 Wiki | 0.41 |
Name (Synonyms) | Correlation | |
---|---|---|
D000856 | Anorexia Nervosa NIH | 0.71 |
D000855 | Anorexia NIH | 0.71 |
D001068 | Feeding and Eating Disorders NIH | 0.45 |
Name (Synonyms) | Correlation |
---|
Navigate: Correlations HPO
There is one clinical trial.
This study looks at the safety and effectiveness of different drugs in treating COVID-19 in people who have been hospitalized with the infection. Participants in the study will be treated with either a study drug plus current standard of care (SOC), or with placebo plus current SOC.
Description: Oxygen requirements measured by 7 categories (1 = least severe, 7 = most severe). The participant's highest (i.e. most severe) observed score is used.
Measure: Pulmonary ordinal outcome (disease severity stratum 1) Time: Day 5Description: Extrapulmonary complications and respiratory dysfunction measured by 7 categories (1= least severe, 7 = most severe). The participant's highest (i.e. most severe) observed score is used.
Measure: Pulmonary+ ordinal outcome (disease severity stratum 1) Time: Day 5Description: Sustained recovery defined as being discharged from the index hospitalization, followed by being alive and home for 14 consecutive days prior to Day 90.
Measure: Time from randomization to sustained recovery Time: Up to Day 90Description: Oxygen requirements measured by 7 categories (1 = least severe, 7 = most severe). The participant's highest (i.e. most severe) observed score is used.
Measure: Pulmonary ordinal outcome Time: Days 1-7, 14 and 28Description: Extrapulmonary complications and respiratory dysfunction measured by 7 categories (1= least severe, 7 = most severe). The participant's highest (i.e. most severe) observed score is used.
Measure: Pulmonary+ ordinal outcome Time: Days 1-7Description: Measured as: Alive at home and no use of continuous supplemental oxygen for an uninterrupted 14 day period
Measure: Incidence of home use of supplemental oxygen above pre-morbid oxygen use Time: 18 monthsDescription: Measured as: Alive at home for an uninterrupted 14 day period and no use of continuous supplemental oxygen at end of 14 day time period.
Measure: Incidence of no home use of supplemental oxygen above pre-morbid oxygen use Time: 14 daysAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports